Nautilus Biotechnolgy
NAUT
81 hedge funds and large institutions have $82.9M invested in Nautilus Biotechnolgy in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 20 reducing their positions, and 14 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 20
6% less funds holding
Funds holding: 86 → 81 (-5)
8.34% less ownership
Funds ownership: 45.28% → 36.93% (-8.3%)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
31% less capital invested
Capital invested by funds: $120M → $82.9M (-$36.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$868K |
| 2 |
BlackRock
New York
|
+$264K |
| 3 |
CGL
Clarius Group LLC
Seattle,
Washington
|
+$160K |
| 4 |
Morgan Stanley
New York
|
+$145K |
| 5 |
State Street
Boston,
Massachusetts
|
+$96.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
-$1.28M |
| 2 |
BM
Bridger Management
New York
|
-$877K |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$790K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$706K |
| 5 |
SGM
Skye Global Management
West Palm Beach,
Florida
|
-$331K |
NAUT Hedge Fund Activity: Q4 2022 in Review
81 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q4 2022, worth a combined $82.9M — down 31% from $120M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of NAUT and 11 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 20 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $868K. The largest seller was Ally Bridge Group, cutting an estimated $1.28M.
- 81 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q4 2022, down from 86 in Q3 2022.
- Funds reported $82.9M of Nautilus Biotechnolgy stock for Q4 2022, down 31% quarter-over-quarter.
- 11 funds opened new Nautilus Biotechnolgy positions in Q4 2022 and 14 closed out, a net change of -3 holders.
- The largest Nautilus Biotechnolgy buyer in Q4 2022 was Anson Funds Management, an estimated $868K added.
- The largest Nautilus Biotechnolgy seller in Q4 2022 was Ally Bridge Group, an estimated $1.28M sold.
Based on aggregated 13F filings for Q4 2022.